ECHELON-2
ECHELON-2 was the first trial in decades to improve on CHOP chemotherapy for T-cell lymphoma: swapping vincristine for the antibody-drug conjugate brentuximab vedotin helped patients live longer, especially those with anaplastic large cell lymphoma.
Overview
ECHELON-2 randomised 452 patients with previously untreated CD30-positive peripheral T-cell lymphoma, about 70 percent of them with systemic anaplastic large cell lymphoma, to six to eight cycles of brentuximab vedotin plus cyclophosphamide, doxorubicin and prednisone (A+CHP) or to standard CHOP. The primary endpoint was progression-free survival by independent review.
A+CHP lengthened progression-free survival and, unusually for a lymphoma trial, overall survival, with a similar rate of peripheral neuropathy to CHOP. It was approved in the United States in November 2018 for CD30-expressing peripheral T-cell lymphomas and is the standard front-line regimen for anaplastic large cell lymphoma; its benefit in the other CD30-positive histologies is less certain because they were a minority of the trial.
Similar pages
not linked directly; found by shared links- TrialALCANZA
Shares Brentuximab vedotin, Takeda, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Pfizer (incl. Seagen) and the tag subtype-trials.
- TrialA Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)
Shares Brentuximab vedotin, Takeda, Prednisone, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma).
- TrialCOG AREN0532
Shares Vincristine, Doxorubicin and the tag subtype-trials.
- TrialZUMA-1
Shares Cyclophosphamide, Non-Hodgkin lymphoma (all types) and the tag subtype-trials.
- TrialCOG ACNS0332
Shares Vincristine, Cyclophosphamide and the tag subtype-trials.
- TrialBrighTNess
Shares Cyclophosphamide, Doxorubicin and the tag subtype-trials.
- TrialPENELOPE-B
Shares Pfizer (incl. Seagen) and the tag subtype-trials.
- TrialZUMA-2
Shares Non-Hodgkin lymphoma (all types) and the tag subtype-trials.